A Real-World Study on Extranodal Lymphoma
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Ruijin Hospital
- Enrollment
- 5,000
- Primary Endpoint
- Progression Free Survival (PFS)
Study Overview
Brief Summary
The aim of this study is to prospectively collect clinical information on patients with extranodal lymphoma, and to explore the best therapeutic strategies in the real-world population.
Detailed Description
Lymphoma is a common hematological malignancy. Many different pathologic types of lymphoma can originate in extranodal organs or be associated with extranodal organ involvement. For lymphoma with extranodal involvement, conventional regimens often cannot provide satisfactory results for patients. This study aims to prospectively collect clinical information on patients with extranodal DLBCL, including the distribution of involved sites, clinical and molecular characteristics of different lymphoma subtypes, clinical treatment protocols, and prognosis, to explore the the best therapeutic strategies in the real-world population.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥ 18 years (including 18 years old).
- •Patients newly diagnosed with non-Hodgkin lymphoma with extranodal involvement, whether it is primary, secondary, or cannot be determined.
- •Patients who have received systematic clinical treatment.
- •Patients with measurable lesions, at least containing one effective evaluation of efficacy.
Exclusion Criteria
- •Patients who only receive supportive treatment.
- •Patients who cannot obtain effective evaluation data of efficacy.
Outcomes
Primary Outcomes
Progression Free Survival (PFS)
Time Frame: Baseline up to data cut-off (up to approximately 1 year)
Progression-Free Survival (PFS) will be defined from the date of starting therapy and the date of disease progression, relapse or death from any cause.
Secondary Outcomes
- Overall Survival (OS)(Baseline up to data cut-off (up to approximately 1 year))
Investigators
Zhao Weili
First Deputy Director, Hematology Department
Ruijin Hospital